Quantitative detection of bcr-abl transcripts in chronic myeloid leukemia

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Optimal management of hematological disorders hinges on effective tumor load reduction.
• Chronic myeloid leukemia (CML) serves as a model for molecular surveillance due to the bcr-abl fusion gene.
• Molecular monitoring of bcr-abl transcripts is vital for assessing treatment response, especially with imatinib therapy.

Purpose of the Study:

• To evaluate the utility of quantitative real-time PCR for monitoring bcr-abl transcript levels.
• To assess treatment response in chronic myeloid leukemia patients undergoing imatinib therapy.

Main Methods:

• Quantitative real-time PCR was employed to measure bcr-abl transcript levels.
• Fifty Tunisian patients with chronic myeloid leukemia in chronic phase were monitored.
• Patient data included treatment duration with imatinib (median 29 months, range 3-60 months).

Main Results:

• Quantitative PCR allows for sensitive detection of residual disease.
• Monitoring bcr-abl transcript levels provides insights into treatment efficacy.
• This approach is essential when cytogenetic analysis falls below detection limits.

Conclusions:

• Quantitative real-time PCR is a valuable tool for molecular monitoring in CML patients treated with imatinib.
• This method aids in assessing treatment response and guiding therapeutic decisions.
• Continued surveillance of bcr-abl transcript levels is recommended for optimal CML management.